Ostomy - Hollister Premier One-Piece

A personalized cancer vaccine conferred a PFS benefit to a subset of patients with newly diagnosed glioblastoma, according to phase 2 study results presented at Society for the Immunotherapy of Cancer Annual Meeting. Patients with primary glioblastoma who had methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoters, as well as those who had mutation of the gene for isocitrate dehydrogenase (IDH), derived a substantial and similar benefit when they received AV-GMB-1 (AiVita Biomedical) in addition to standard aggressive therapy, Daniela A. Bota, MD, PhD, ...

>Read More

Higher inhaled corticosteroid dose may be a risk factor for Pseudomonas aeruginosa infection in patients with severe COPD, according to data published in BMJ Open Respiratory Research. The relationship between inhaled corticosteroid use and the risk of Pseudomonas aeruginosa infection and its clinical consequences in patients with COPD are not well established and could modify the indication of this treatment in patients with COPD with frequent exacerbations caused by P. aeruginosa, Hanaa Shafiek, MD, associate professor in the department of chest diseases at Alexandria ...

>Read More

Vyjuvek was effective in healing the majority of dystrophic epidermolysis bullosa wounds in a phase 3 trial, Krystal Biotech announced in a press release. An investigational noninvasive topical gene therapy, Vyjuvek (beremagene geperpavec or B-VEC), delivers two copies of the COL7A1 gene to epidermolysis bullosa wounds. The randomized, double-blind, intra-patient placebo-controlled phase 3 GEM-3 trial included 31 patients with primary matched wound pairs. Complete wound healing, as assessed by investigators, was reported in 67% of those treated with Vyjuvek at 6-month timepoints, compared to 22% ...

>Read More

LensGen has received approval for an investigational device exemption from the FDA, paving the way for a pivotal study of the Juvene IOL, according to a company press release. We are proud to achieve this significant milestone for the company, which allows us to move forward with the IDE pivotal trial with the ultimate goal of seeking premarket approval in the largest eye care market in the world, Ramgopal Rao, CEO of LensGen said in a press release. Achieving IDE approval of a novel device is a tremendous undertaking and enormous accomplishment for the company, and we are grateful to the ...

>Read More

In this video, R. Michael Meneghini, MD, discusses how the recent funding received by M2 Orthopedic Partners will broaden its ability to support research and education interests among orthopedic practices. One of the unique aspects of M2 Orthopedic Partners is that we are attracted to orthopedic surgeons who have an interest in research and education, Meneghini, co-founder and chief medical officer of M2 Orthopedic Partners, told Healio Orthopedics. The orthopedic management platforms that are backed by private equity are emerging as a way to help keep physicians more ...

>Read More

Among patients with fibrotic interstitial lung disease, low BMI and weight loss were independently associated with increased 1-year mortality, researchers reported in Chest. BMI and weight loss may be clinically useful prognostic indicators in patients with fibrotic ILD, the researchers concluded. Weight loss is similarly a harbinger of poor outcomes in various chronic lung diseases including COPD, asthma and bronchiectasis. Some studies have suggested an association of mortality with both BMI and change in weight in fibrotic ILD, but others have not found this association, ...

>Read More

The FDA granted fast track designation to arfolitixorin for treatment of patients with metastatic colorectal cancer. Arfolitixorin (Isofol Medical AB) is a stabilized and biologically active pure form of folate ([6R]-5,10-methylenetetrahydrofolic acid). The randomized phase 3 AGENT study is underway to assess the agent, designed to increase the efficacy of standard chemotherapy. Researchers will assign 440 patients to 5-FU, oxaliplatin and bevacizumab (Avastin, Genentech) plus either arfolitixorin or leucovorin as first-line treatment for metastatic colorectal cancer. The primary endpoint is ...

>Read More

Product Listings for Ostomy - Hollister Premier One-Piece